Mezzion Pharmaceuticals Secures $20 Million in Strategic Investment

Summary:

1. Mezzion Pharma, a company based in Seoul, South Korea, has secured $20M USD in strategic funding for its clinical development programs.
2. The funding round was led by Midas-Meritz New Technology Finance Association and KDBC-Korea Investment & Securities New Technology Investment Association.
3. Mezzion Pharma plans to use the funds to support the global Phase 3 FUEL-2 trial of udenafil for patients with Fontan circulation, a rare congenital heart condition.

   —

   Mezzion Pharma, a pharmaceutical company headquartered in Seoul, South Korea, has recently announced a significant milestone in its efforts to develop treatments for rare and underserved diseases. The company successfully raised approximately $20M USD in strategic funding, with leading contributions from Midas-Meritz New Technology Finance Association and KDBC-Korea Investment & Securities New Technology Investment Association.

   This latest funding boost will be instrumental in supporting Mezzion Pharma’s ongoing global Phase 3 FUEL-2 trial of udenafil, a promising therapy designed for patients with Fontan circulation. Fontan physiology is a rare congenital heart condition that affects a small population, making it a challenging disease to address. By advancing udenafil through clinical trials, Mezzion Pharma aims to provide much-needed treatment options for individuals living with this condition.

   Under the leadership of CEO Dean Park, Mezzion Pharma’s U.S. subsidiary, Mezzion Pharmaceuticals, Inc., based in New Jersey, spearheads the company’s global clinical development and commercialization efforts. The focus on developing innovative therapies for rare diseases reflects Mezzion Pharma’s commitment to making a meaningful impact in the healthcare industry.

   In conclusion, Mezzion Pharma’s successful funding round and dedication to advancing treatments for Fontan circulation highlight the company’s strides in addressing unmet medical needs. With the support of strategic investors, Mezzion Pharma is well-positioned to make significant advancements in the field of rare disease therapeutics.